Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.79 billion
  • Outstanding Shares: 54,955,000
Average Prices:
  • 50 Day Moving Avg: $32.74
  • 200 Day Moving Avg: $32.30
  • 52 Week Range: $14.83 - $63.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.06
  • P/E Growth: 187.95
Sales & Book Value:
  • Annual Revenue: $21.76 million
  • Price / Sales: 82.05
  • Book Value: $7.81 per share
  • Price / Book: 4.16
  • EBIDTA: ($236,660,000.00)
  • Return on Equity: -97.14%
  • Return on Assets: -73.56%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 6.70%
  • Quick Ratio: 6.65%
  • Average Volume: 2.22 million shs.
  • Beta: 1.87
  • Short Ratio: 3.81

Frequently Asked Questions for Sarepta Therapeutics (NASDAQ:SRPT)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) released its quarterly earnings data on Thursday, April, 27th. The company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.12. The firm had revenue of $16.34 million for the quarter, compared to analyst estimates of $13.80 million. The company's revenue was up 163300.0% compared to the same quarter last year. During the same period last year, the business earned ($1.15) EPS. View Sarepta Therapeutics' Earnings History.

When will Sarepta Therapeutics make its next earnings announcement?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 17th 2017. View Earnings Estimates for Sarepta Therapeutics.

Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2017?

19 equities research analysts have issued 12-month target prices for Sarepta Therapeutics' shares. Their forecasts range from $27.00 to $102.00. On average, they anticipate Sarepta Therapeutics' share price to reach $61.10 in the next year. View Analyst Ratings for Sarepta Therapeutics.

What are analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

  • 1. Cowen and Company analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
  • 2. Instinet analysts commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant upside to materialize as Exondys 51 launch metrics begin to reflect an underestimated demand for the treatment and the ultimate patient numbers/market opportunity. We expect additional upside to be realized following EU approval of Exondys 51, which will help bolster perception of the drug's benefit and to define the EU opportunity, currently not reflected in shares." (3/1/2017)
  • 3. Needham & Company LLC analysts commented, "As previously reported, Sarepta earned $5.4M in 4Q16 Exondys revenue. The company gave 1Q and FY17 guidance for Exondys sales of $13-15M and >$80M, respectively. While the 1Q guidance number is relatively in line with our ($17M) and the Street's estimates, the low end of FY17 guidance is significantly below expectations and implies no acceleration in new patient starts through the back part of 2017. This sales guidance contrasts with management's qualitative commentary about accelerating conversion rates and we believe is explained by conservatism in an uncertain and dynamic reimbursement environment. We continue to expect that the majority of the 1,400+ eligible DMD boys in the US will ultimately be on therapy by implying a ~$400M Exondys US sales run rate." (3/1/2017)
  • 4. Royal Bank of Canada analysts commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT -15%AH). We didn't hear anything on the call to justify this level of selling: while FY17 guidance appears soft to us (>$80M) and doesn't exude confidence, guidance for 1Q17 ($13-$15 vs. $5.4M in 4Q16) and management's language about conversion rate acceleration, makes us view the >$80M guidance as beatable." (3/1/2017)
  • 5. Robert W. Baird analysts commented, "Sarepta provided initial sales guidance for Exondys 51, coming in at consensus for Q1 and putting an $80M floor on full-year sales. We think the market is misinterpreting the >$80M guidance as a point estimate rather than a floor. We remain confident that full-year sales should easily exceed $80M and a reset on expectations helps to remove some revision headwinds facing the stock." (3/1/2017)

Who are some of Sarepta Therapeutics' key competitors?

Who owns Sarepta Therapeutics stock?

Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.66%), Vanguard Group Inc. (7.47%), State Street Corp (5.82%), Perceptive Advisors LLC (3.22%), Camber Capital Management LLC (2.46%) and FMR LLC (2.05%). Company insiders that own Sarepta Therapeutics stock include David T Howton, Edward M Md Kaye, Jayant Aphale, M Kathleen Behrens and Sandesh Mahatme. View Institutional Ownership Trends for Sarepta Therapeutics.

Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Point72 Asset Management L.P., FMR LLC, Granite Point Capital Management L.P., SG Americas Securities LLC, Morgan Stanley, TIAA CREF Investment Management LLC and First Trust Advisors LP. Company insiders that have sold Sarepta Therapeutics stock in the last year include David T Howton, Edward M Md Kaye, Jayant Aphale and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.

Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Camber Capital Management LLC, State Street Corp, Pinnacle Associates Ltd., Emerald Advisers Inc. PA, Elk Creek Partners LLC, Emerald Mutual Fund Advisers Trust and Vanguard Group Inc.. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sarepta Therapeutics stock cost?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $32.49.

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 2 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.95)
Consensus Price Target: $61.10 (88.06% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017NomuraReiterated RatingBuy$84.00MediumView Rating Details
5/18/2017Piper Jaffray CompaniesSet Price TargetBuy$43.00HighView Rating Details
5/2/2017SunTrust Banks, Inc.Reiterated RatingBuy$45.00LowView Rating Details
5/2/2017Oppenheimer Holdings Inc.Reiterated RatingOutperform$76.00LowView Rating Details
4/29/2017Leerink SwannReiterated RatingOutperform$47.00 -> $52.00MediumView Rating Details
4/28/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
4/28/2017Credit Suisse Group AGReiterated RatingOutperform$64.00LowView Rating Details
4/28/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$91.00 -> $60.00HighView Rating Details
4/23/2017Robert W. BairdReiterated RatingOutperform$102.00HighView Rating Details
4/6/2017Jefferies Group LLCReiterated RatingHold$27.00MediumView Rating Details
3/11/2017JPMorgan Chase & Co.Set Price TargetBuy$42.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$84.00N/AView Rating Details
3/1/2017Needham & Company LLCLower Price TargetBuy$78.00 -> $75.00N/AView Rating Details
3/1/2017JMP SecuritiesLower Price Target$48.00N/AView Rating Details
1/4/2017Morgan StanleyLower Price TargetEqual -> Weight$53.00 -> $33.00N/AView Rating Details
1/3/2017Janney Montgomery ScottUpgradeNeutral -> Buy$27.43 -> $65.00N/AView Rating Details
12/20/2016Goldman Sachs Group IncInitiated CoverageNeutral$40.00N/AView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00N/AView Rating Details
10/2/2016William BlairReiterated RatingOutperform$88.00N/AView Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00N/AView Rating Details
5/5/2016Ladenburg Thalmann Financial ServicesDowngradeMarket Perform -> Underperform$13.00 -> $5.00N/AView Rating Details
11/8/2015Roth CapitalReiterated RatingBuy$50.00N/AView Rating Details
10/23/2015Bank of America CorpInitiated CoverageBuy$49.00N/AView Rating Details
9/1/2015Susquehanna Bancshares IncBoost Price TargetNeutral$33.00 -> $36.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Earnings History by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($0.85)($0.73)$13.80 million$16.34 millionViewN/AView Earnings Details
2/28/2017Q416($1.33)($0.71)$4.86 million$5.42 millionViewListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.19)($1.35)$1.10 millionViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
2017 EPS Consensus Estimate: ($2.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176($1.15)$0.57($0.65)
Q2 20176($1.02)$1.22($0.26)
Q3 20176($0.99)$0.54($0.57)
Q4 20176($0.97)$0.53($0.54)
(Data provided by Zacks Investment Research)


Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 76.75%
Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.00View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.00View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.00View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.00View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.00View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.00View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sarepta Therapeutics (NASDAQ:SRPT)
Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline logoSarepta Therapeutics Inc (SRPT) Downgraded to Hold at Vetr Inc. - May 22 at 10:54 PM logoWhy Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today - May 22 at 6:02 PM logoI'm Surprised That They're Surprised - May 20 at 7:31 PM logoSarepta Therapeutics Inc (SRPT) PT Set at $43.00 by Piper Jaffray Companies - May 19 at 7:16 PM logo​Former Sarepta CEO launches biotech accelerator with $25M backing - May 18 at 12:57 PM logoHow the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked - May 18 at 12:57 PM logoSarepta Therapeutics Inc (SRPT) Stock Rating Upgraded by Vetr Inc. - May 9 at 12:39 AM logoSarepta Therapeutics Inc (SRPT) Raised to "Strong-Buy" at Vetr Inc. - May 9 at 12:18 AM logoSarepta Therapeutics Inc. Stock Rose 22.5% in April. Here's Why. - May 6 at 10:26 AM logoSarepta Therapeutics Inc. Stock Rose 22.5% in April. Here's Why. - May 6 at 7:34 AM logo Analysts Anticipate Sarepta Therapeutics Inc (SRPT) Will Post Quarterly Sales of $21.8 Million - May 5 at 3:32 PM logoSomewhat Positive News Coverage Very Likely to Affect Sarepta Therapeutics (SRPT) Stock Price - May 3 at 9:24 PM logoSarepta Therapeutics May Attract Activist Attention - - May 3 at 10:38 AM logo-$0.92 EPS Expected for Sarepta Therapeutics Inc (SRPT) This Quarter - May 3 at 9:42 AM logoSarepta Therapeutics Inc (SRPT) Receives Buy Rating from SunTrust Banks, Inc. - May 2 at 5:16 PM logoOppenheimer Holdings Inc. Reiterates Outperform Rating for Sarepta Therapeutics Inc (SRPT) - May 2 at 1:27 PM logoSarepta: Forget a Takeover. This is Why Its CEO's Departure Could Be Good News - May 1 at 7:11 PM logoSarepta Therapeutics Inc (SRPT) Given Consensus Recommendation of "Buy" by Brokerages - May 1 at 6:18 PM logoFY2021 EPS Estimates for Sarepta Therapeutics Inc Decreased by SunTrust Banks (SRPT) - May 1 at 3:06 PM logoFY2020 EPS Estimates for Sarepta Therapeutics Inc Raised by Analyst (SRPT) - May 1 at 3:04 PM logoHow Much Would Sarepta Therapeutics Fetch in a Buyout? - May 1 at 2:19 PM logoToday's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics - May 1 at 11:31 AM logoSarepta Therapeutics (SRPT) Given Daily Media Sentiment Score of 0.36 - April 30 at 2:23 PM logoSarepta Therapeutics Inc (SRPT) Earns Outperform Rating from Leerink Swann - April 29 at 11:52 PM logoCowen and Company Reiterates Buy Rating for Sarepta Therapeutics Inc (SRPT) - April 29 at 1:01 AM logoSarepta Therapeutics Inc (SRPT) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS - April 29 at 12:08 AM logoSarepta Therapeutics Inc (SRPT) Stock Rating Reaffirmed by Credit Suisse Group AG - April 28 at 11:24 PM logoSarepta Therapeutics Inc (SRPT) Releases Earnings Results, Beats Expectations By $0.12 EPS - April 28 at 6:46 PM logoEdited Transcript of SRPT earnings conference call or presentation 27-Apr-17 8:30pm GMT - April 28 at 4:13 PM logoSarepta Tests Biotech's CEO Vacuum Hypothesis - April 28 at 4:13 PM logoSarepta Pops On Consensus-Topping Revenue, Boosts 2017 Guide - April 28 at 4:13 PM logoHere's Why Sarepta Therapeutics May Be The Rarest Of Finds: A 'Value' Biotech Stock - April 28 at 2:49 PM logoExondys Sales, Takeover Speculation Fuel Sarepta Therapeutics - April 28 at 11:48 AM logoSarepta Therapeutics Inc (SRPT) Given New $60.00 Price Target at Royal Bank of Canada - April 28 at 9:22 AM logoSarepta Therapeutics' (SRPT) CEO Ed Kay on Q1 2017 Results - Earnings Call Transcript - April 28 at 1:17 AM logoInvestor Network: Sarepta Therapeutics, Inc. to Host Earnings Call - April 28 at 1:17 AM logoSarepta Therapeutics' (SRPT) Ed Kaye to Resign as CEO - - April 27 at 8:15 PM logoSarepta Therapeutics tops Street 1Q forecasts - April 27 at 5:18 PM logoSomewhat Positive Press Coverage Extremely Likely to Impact Sarepta Therapeutics (SRPT) Share Price - April 27 at 4:26 PM logoSarepta expectations too high - Janney - Seeking Alpha - April 27 at 5:49 AM logoSarepta: A Victim of High Expectations? - April 26 at 4:24 PM logoSarepta Therapeutics Inc (SRPT) Downgraded by Vetr Inc. - April 25 at 12:30 AM logoSRPT Makes Bullish Cross Above Critical Moving Average - April 24 at 6:23 PM logoSarepta Therapeutics (SRPT) Earns News Sentiment Score of 0.34 - April 24 at 4:30 PM logoSarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers - April 24 at 11:22 AM logoSarepta Therapeutics Inc (SRPT) Receives Outperform Rating from Robert W. Baird - April 23 at 12:50 PM logo[$$] Drugmaker Sarepta's Stock Could Double - April 22 at 11:33 AM logoSarepta Therapeutics (SRPT) Getting Favorable Press Coverage, AlphaOne Reports - April 21 at 6:59 PM logoLeerink Swann Comments on Sarepta Therapeutics Inc's FY2019 Earnings (SRPT) - April 20 at 4:28 PM logoScott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, - PR Newswire (press release) - April 20 at 8:00 AM



Sarepta Therapeutics (SRPT) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff